Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ENB Therapeutics

Request full access

ENB Therapeutics is developing therapies to break barriers that prevent the majority of patients from responding to immunotherapy agents

New York City, United StatesFounded 2015Biotech & Life Sciences

About ENB Therapeutics

ENB Therapeutics is a clinical-stage biopharmaceutical company focused on addressing the significant challenge of drug resistance in cancer therapy. The firm was co-founded by Sumant Ramachandra, a seasoned pharmaceutical executive with experience at companies like Pfizer and Baxter, and Zachary Hornby. Ramachandra's background in drug development and corporate strategy, combined with Hornby's expertise in business development and operations, provided the foundational leadership for the company's mission. The company's core focus is the development of treatments that can overcome resistance to immunotherapy, a problem observed in a substantial portion of cancer patients. ENB Therapeutics operates within the oncology market, specifically targeting the multi-billion dollar immunotherapy sector. Its business model centers on the research, clinical development, and eventual commercialization of proprietary drug candidates. Revenue generation is anticipated through partnerships, licensing agreements with larger pharmaceutical companies, and ultimately, sales of its approved therapies. ENB's lead product candidate is ENB-001, a first-in-class small molecule inhibitor of the endothelin B receptor (ETBR).

Source: Dealroom company data

At a glance

Founded
2015
Headquarters
New York City, United States
Sector
Biotech & Life Sciences

ENB Therapeutics in the New York City ecosystem

Live from Dealroom

The ENB Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Remiges Ventures
  • BioAdvance
  • Alexandria Venture Investments

Series B and later6 investors entered at this stage

  • Pipeline Angels
  • Avestria Ventures
  • AJI Capital
  • Springboard Enterprises
  • Accelerate New York Seed Fund
  • Alexandria LaunchLabs
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ENB Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ENB Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.